ARS Pharmaceuticals' EpiPen Alternative Delayed US Approval - Two Analysts Offer Differing Views
Portfolio Pulse from Vandana Singh
The FDA has issued a Complete Response Letter regarding ARS Pharmaceuticals Inc's New Drug Application for neffy, an EpiPen alternative. This has delayed the approval and launch of neffy in the U.S. Wedbush analysts remain bullish on the stock, but have cut the price target from $15 to $5. William Blair downgraded the stock to a Market Perform rating due to extended timelines and heightened risk.
September 21, 2023 | 7:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ARS Pharmaceuticals' stock may face volatility due to the FDA's delay in approving neffy and differing analyst views. Wedbush remains bullish but has cut the price target, while William Blair has downgraded the stock.
The FDA's delay in approving neffy, an EpiPen alternative, has led to differing views among analysts. This could lead to volatility in ARS Pharmaceuticals' stock price. Wedbush remains bullish but has cut the price target from $15 to $5, indicating a potential downside. Meanwhile, William Blair has downgraded the stock to a Market Perform rating, suggesting that the stock may not outperform the market in the near term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100